Search

Sarepta Therapeutics Inc

Închisă

SectorSănătate

18.8 4.27

Rezumat

Modificarea prețului

24h

Curent

Minim

17.86

Maxim

18.69

Indicatori cheie

By Trading Economics

Venit

-4.9M

326M

Vânzări

-330M

401M

P/E

Medie Sector

42.919

57.371

EPS

0.42

Marjă de profit

81.263

Angajați

835

EBITDA

-345M

30M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+21.71% upside

Dividende

By Acuity

Următoarele câștiguri

2 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

244M

1.9B

Deschiderea anterioară

14.53

Închiderea anterioară

18.8

Sentimentul știrilor

By Acuity

50%

50%

147 / 340 Clasament în Healthcare

Sarepta Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 aug. 2026, 19:26 UTC

Sarepta Therapeutics Inc is trading lower today, with no specific news identified for the decline. Broader market trends show a rebound in U.S. stocks.

20 aug. 2026, 23:56 UTC

Sarepta Therapeutics Inc. shares traded roughly flat in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

19 aug. 2026, 23:11 UTC

Sarepta Therapeutics shares are lower in after-market hours amid a broader decline in the Biotechnology sub-sector, showing unusual volatility during the session.

18 aug. 2026, 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, retracing gains amid broader market weakness linked to rising sovereign bond yields and inflation concerns.

17 aug. 2026, 19:36 UTC

Sarepta Therapeutics Inc shares are higher, continuing their advance since Friday's close and trading above the 20-day moving average. No specific news was identified.

14 aug. 2026, 19:36 UTC

Sarepta Therapeutics shares are lower today amid broader market sentiment following a reported decline in retail sales for July. No specific company news was identified.

13 aug. 2026, 19:36 UTC

Sarepta Therapeutics shares are trading roughly flat, with no specific news identified. The price remains significantly above the 20-day moving average.

12 aug. 2026, 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, continuing a decline since Wednesday's close, with no specific news identified to explain the drop.

11 aug. 2026, 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement amid broader market focus on inflation data.

10 aug. 2026, 23:52 UTC

Sarepta Therapeutics shares are lower in after-market hours, with no specific news identified for the decline amid broader market sentiment influenced by labor report data.

7 aug. 2026, 19:36 UTC

News

Sarepta Therapeutics reports Q2 2026 revenue of $401.3 million, down from $611.1 million a year earlier, with shares trading lower during the session.

6 aug. 2026, 20:03 UTC

Social Media
News

Sarepta Therapeutics shares are higher following strong Q2 results, with adjusted EPS of $0.64 and revenue of $401.3 million exceeding estimates.

5 aug. 2026, 23:11 UTC

News
Social Media

Sarepta Therapeutics reported Q2 adjusted EPS of $0.64, exceeding estimates. Revenue reached $401.3 million, driving shares higher in after-market trading.

4 aug. 2026, 19:31 UTC

Sarepta Therapeutics is higher today, benefiting from strong tech stock performance and increased U.S. manufacturing activity, despite pulling back earlier in the session.

3 aug. 2026, 20:03 UTC

Sarepta Therapeutics Inc shares are higher today, reflecting broader market strength. The S&P 500 and Nasdaq 100 have also advanced during the session.

30 iul. 2026, 19:58 UTC

Sarepta Therapeutics Inc shares are lower today, with no specific news driving the decline. The stock is trading significantly below its 20-day moving average.

29 iul. 2026, 22:06 UTC

News

Sarepta Therapeutics granted inducement stock options to CEO Dr. Michael Severino, with shares trading higher in after-market hours following the announcement.

28 iul. 2026, 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours amid a broader market decline, with no specific news identified to explain the movement.

27 iul. 2026, 23:16 UTC

Social Media

Sarepta Therapeutics appoints Michael Severino as CEO, effective July 28. Shares are higher in after-market trading following the leadership change.

21 iul. 2026, 17:51 UTC

Sarepta Therapeutics shares are lower today, pulling back from earlier session highs amid no specific news. The stock remains near the lower end of its one-month range.

Comparație

Modificare preț

Sarepta Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

21.71% sus

Prognoză pe 12 luni

Medie 22.87 USD  21.71%

Maxim 38 USD

Minim 5 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSarepta Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

16 ratings

5

Cumpărare

7

Păstrare

4

Vânzare

Sentiment

By Acuity

147 / 340 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat